Literature DB >> 8329288

Studies on the renal excretion of the acyl glucuronide, phenolic glucuronide and sulphate conjugates of diflunisal.

R G Dickinson1, A R King, G E McKinnon, W D Hooper, M J Eadie, G K Herkes.   

Abstract

1. In five healthy male volunteers given multiple doses of diflunisal (DF), renal clearances (CLR) of the acyl glucuronide (DAG), phenolic glucuronide (DPG) and sulphate (DS) conjugates were about 42, 25 and 13 ml min-1, respectively. 2. These relatively low CLR values are probably due largely to the very high plasma protein binding of the conjugates, found in vitro to be 99.0%, 97.8% and 99.45%, respectively. 3. Thus glomerular filtration plays the minor and active tubular secretion the major role in renal excretion of the three conjugates. 4. This conclusion was supported by the effect of probenecid co-administration, which decreased CLR of DAG and DPG by about 70%. CLR for DS could not be calculated when probenecid was co-administered (because of interference by probenecid metabolites in the analysis of DS in urine). 5. Water-induced diuresis had no effect on CLR of the DF conjugates, consistent with tubular reabsorption being negligible.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8329288      PMCID: PMC1381604          DOI: 10.1111/j.1365-2125.1993.tb04190.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

Review 1.  Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism?

Authors:  H Spahn-Langguth; L Z Benet
Journal:  Drug Metab Rev       Date:  1992       Impact factor: 4.518

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Disposition and irreversible plasma protein binding of tolmetin in humans.

Authors:  M L Hyneck; P C Smith; A Munafo; A F McDonagh; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  1988-07       Impact factor: 6.875

4.  Reactivity considerations in the analysis of glucuronide and sulfate conjugates of diflunisal.

Authors:  R G Dickinson; A R King
Journal:  Ther Drug Monit       Date:  1989-11       Impact factor: 3.681

5.  Covalent binding of diflunisal and probenecid to plasma protein in humans: persistence of the adducts in the circulation.

Authors:  G E McKinnon; R G Dickinson
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1989-12

6.  Probenecid-induced changes in the clearance of carprofen enantiomers: a preliminary study.

Authors:  H Spahn; I Spahn; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  1989-05       Impact factor: 6.875

7.  Effect of probenecid on the formation and elimination of acyl glucuronides: studies with zomepirac.

Authors:  P C Smith; P N Langendijk; J A Bosso; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  1985-08       Impact factor: 6.875

Review 8.  Clinical pharmacokinetics of probenecid.

Authors:  R F Cunningham; Z H Israili; P G Dayton
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

9.  Effects of probenecid on ketoprofen kinetics.

Authors:  R A Upton; R L Williams; J N Buskin; R M Jones
Journal:  Clin Pharmacol Ther       Date:  1982-06       Impact factor: 6.875

10.  Effect of dose on the glucuronidation and sulphation kinetics of diflunisal in man: single dose studies.

Authors:  G R Loewen; R J Herman; S G Ross; R K Verbeeck
Journal:  Br J Clin Pharmacol       Date:  1988-07       Impact factor: 4.335

View more
  2 in total

Review 1.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

2.  Effect of probenecid on the formation and elimination kinetics of the sulphate and glucuronide conjugates of diflunisal.

Authors:  J I Macdonald; S M Wallace; R J Herman; R K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.